7:02AM Auxilium Pharma announces results from 3 year CORDLESS extension study in dupuytren's contracture (AUXL) 19.61 : Co says 34.8% of joints that had achieved clinical success had experienced recurrence. Of those patients with affected MP joints, 26.6% of joints that had achieved clinical success had recurrence through three years, while 56.4% of PIP joints that had achieved clinical success had recurrence through three years. In addition, -93% of joints that were successfully treated with XIAFLEX did not receive any medical or surgical intervention through three years of follow-up.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.